103 related articles for article (PubMed ID: 38872982)
1. Time course of hypertension and myocardial dysfunction following anthracycline chemotherapy in pediatric patients.
Jacquemyn X; Zhan J; Van den Eynde J; Cordrey K; Long R; Rao S; Barnes BT; Thompson WR; Danford D; Kutty S
Int J Cardiol Heart Vasc; 2024 Aug; 53():101436. PubMed ID: 38872982
[TBL] [Abstract][Full Text] [Related]
2. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
[TBL] [Abstract][Full Text] [Related]
3. Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection.
Giang M N; Nguyen H H; Vo DT; Ho Huynh Quang T; Phan DTH; Chau NH
Open Heart; 2023 Nov; 10(2):. PubMed ID: 38011990
[TBL] [Abstract][Full Text] [Related]
4. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
[TBL] [Abstract][Full Text] [Related]
5. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.
Nhat GM; Hai NH; Duc VT; Tri HHQ; Hoa CN
Front Cardiovasc Med; 2024; 11():1291180. PubMed ID: 38312233
[TBL] [Abstract][Full Text] [Related]
6. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy.
Thavendiranathan P; Negishi T; Somerset E; Negishi K; Penicka M; Lemieux J; Aakhus S; Miyazaki S; Shirazi M; Galderisi M; Marwick TH;
J Am Coll Cardiol; 2021 Feb; 77(4):392-401. PubMed ID: 33220426
[TBL] [Abstract][Full Text] [Related]
7. Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma.
Nakayama T; Oshima Y; Shintani Y; Yamamoto J; Yokoi M; Ito T; Wakami K; Kitada S; Goto T; Hashimoto H; Kusumoto S; Sugiura T; Iida S; Seo Y
Circ Rep; 2022 Apr; 4(4):173-182. PubMed ID: 35434414
[No Abstract] [Full Text] [Related]
8. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Subclinical Deterioration of Right Ventricular Function by Three-Dimensional Speckle Tracking Echocardiography in Breast Cancer Patients Undergoing Anthracycline-Based Chemotherapy.
Xu H; Mao L; Liu H; Zhang Y; Yang J
Int J Gen Med; 2021; 14():885-893. PubMed ID: 33758535
[TBL] [Abstract][Full Text] [Related]
11. Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: a case control study.
Boen HM; Alaerts M; Goovaerts I; Saenen JB; Franssen C; Vorlat A; Vermeulen T; Heidbuchel H; Van Laer L; Loeys B; Van Craenenbroeck EM
Cardiooncology; 2024 Apr; 10(1):26. PubMed ID: 38689299
[TBL] [Abstract][Full Text] [Related]
12. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction.
Saijo Y; Kusunose K; Okushi Y; Yamada H; Toba H; Sata M
Heart; 2020 Nov; 106(22):1752-1758. PubMed ID: 32209616
[TBL] [Abstract][Full Text] [Related]
13. Impact of hypertension on left ventricular function in patients after anthracycline chemotherapy for malignant lymphoma.
Tanaka Y; Tanaka H; Hatazawa K; Yamashita K; Sumimoto K; Shono A; Suzuki M; Yokota S; Suto M; Mukai J; Takada H; Matsumoto K; Minami H; Hirata KI
Int J Cardiol; 2021 Jan; 323():126-132. PubMed ID: 32800904
[TBL] [Abstract][Full Text] [Related]
14. Red Blood Cell Distribution Width Is a Predictive Factor of Anthracycline-Induced Cardiotoxicity.
Yaegashi D; Oikawa M; Yokokawa T; Misaka T; Kobayashi A; Kaneshiro T; Yoshihisa A; Nakazato K; Ishida T; Takeishi Y
Front Cardiovasc Med; 2020; 7():594685. PubMed ID: 33330656
[No Abstract] [Full Text] [Related]
15. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
[TBL] [Abstract][Full Text] [Related]
16. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
17. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
Tahir E; Azar M; Shihada S; Seiffert K; Goy Y; Beitzen-Heineke A; Molwitz I; Muellerleile K; Stehning C; Schön G; Adam G; Petersen C; Müller V; Lund GK
Eur Radiol; 2022 Mar; 32(3):1853-1865. PubMed ID: 34536111
[TBL] [Abstract][Full Text] [Related]
18. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
Glen C; Adam S; McDowell K; Waterston A; Tan YY; Petrie MC; Coats CJ; Lang NN
JACC CardioOncol; 2023 Oct; 5(5):628-637. PubMed ID: 37969652
[TBL] [Abstract][Full Text] [Related]
20. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study.
Liu J; Cao Y; Zhu K; Yao S; Yuan M; Kong X; Liu X; Li Y; Cui Y; Han X; Zhou X; Meng R; Shi H
Quant Imaging Med Surg; 2022 Oct; 12(10):4771-4785. PubMed ID: 36185042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
